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ABSTRACT
Leclercia adecarboxylata is an opportunistic human pathogen that phenotypically resembles Escherichia
coli. The natural susceptibilities of 101 Leclercia strains to 70 antimicrobial agents were investigated.
MICs were determined with a microdilution procedure in cation-adjusted Mueller–Hinton broth (all
strains) and IsoSensitest broth (some strains). Natural susceptibility patterns were assessed using
German (DIN) standards (when applicable). In addition, biochemical properties recommended for the
phenotypic identification of L. adecarboxylata were evaluated, applying two commercially available
identification systems for Enterobacteriaceae and seven conventional tests. L. adecarboxylata strains were
naturally sensitive to tetracyclines, aminoglycosides, all but two b-lactams, quinolones, folate pathway
inhibitors, chloramphenicol, nitrofurantoin and azithromycin. They were naturally resistant to penicillin
G, oxacillin, erythromycin, roxithromycin, clarithromycin, ketolides, lincosamides, streptogramins,
linezolid, glycopeptides, rifampicin, fusidic acid and fosfomycin. There were only minor medium-
dependent differences in susceptibility to most antibiotics. Lysine decarboxylase, malonate assimilation
and acid production from arabitol and cellobiose, but not from adonitol and sorbitol, allowed definitive
separation of L. adecarboxylata from E. coli. The results of this study form a database that can be applied
to validate forthcoming antibiotic susceptibility tests of L. adecarboxylata, and might contribute to its
reliable identification. Susceptibility patterns did not indicate obvious therapeutic difficulties for
treatment of Leclercia infections. Special attention should be paid to biochemically aberrant leclerciae.
Apart from biochemical features, fosfomycin susceptibility might be useful to differentiate between
L. adecarboxylata and E. coli.
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INTRODUCTION
In 1962, Leclerc described pigmented Enterobac-
teriaceae [1], which were designated initially as
‘Enteric group 41’ or ‘Escherichia adecarboxylata’
[2]. Based on nucleic acid and protein electroph-
oretic techniques, ‘E. adecarboxylata’ was separ-
ated from the ‘Enterobacter agglomerans’ complex
[3] to which it had been assigned temporarily, and
renamed as Leclercia adecarboxylata [4]. Strains of
L. adecarboxylata share the characteristics of typical
Enterobacteriaceae and comprise Gram-negative,
facultative-anaerobic, oxidase-negative, mesophi-
lic, peritrich-flagellated bacilli, with a G + C
content of 52–54% [2,4–6]. However, in contrast
to several other members of this family, entero-
bacterial common antigen was not detected in
L. adecarboxylata [7]. Leclerciae are distributed
widely in nature and have been isolated from
food, water and other environmental sources
[4,6,8], and also from various clinical specimens,
including blood, faeces, sputum, urine and
wound pus [4,6].
The clinical significance of L. adecarboxylata is
not well-defined. Until recently, there were few
reports of human infections associated with this
species [9–12], but several publications since July
1997 have described L. adecarboxylata as a ‘novel’
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opportunistic human pathogen [13–20]. However,
based on the available data and personal experi-
ence, it seems possible that infections attributed to
L. adecarboxylata are underestimated and have
been under-reported for several decades. It is
likely that the postulated underestimation of
Leclercia infections results from misidentification
of several leclerciae as Escherichia coli, since both
species share several biochemical features [4,21].
As L. adecarboxylata forms colonies resembling
those of E. coli on MacConkey medium, deso-
xycholate–lactose, and eosin–methylene blue
agars, and gives the same results as E. coli in the
IMViC system, it is easily confused with E. coli in
the routine laboratory if not investigated further
[4]. In addition, several leclerciae are unable to
produce acid from adonitol, but are able to
ferment sorbitol, which is a biochemical pattern
characteristic of E. coli [21].
The main aim of the present study was to create
a database of the natural susceptibility of well-
characterised strains of L. adecarboxylata to a wide
range of antimicrobial agents. In particular, it was
of interest to identify any species-related differ-
ences in susceptibility between L. adecarboxylata
and E. coli. Published data on antimicrobial
susceptibility patterns of Leclercia generally refer
to one or a few strains and a low number of
antibiotics; data on the natural antimicrobial
susceptibilities of L. adecarboxylata have not been
published previously. In addition, this study
evaluated the use of biochemical properties for
the phenotypic identification of Leclercia.
MATERIALS AND METHODS
Bacterial strains
One hundred strains labelled as ‘L. adecarboxylata’ were
kindly provided by G. Stempfel (Weingarten, Germany).
These strains were collected between January 1992 and April
1997 (1992, n = 12; 1993, n = 11; 1994, n = 20; 1995, n = 20;
1996, n = 28; 1997, n = 9) and were isolated from clinical
specimens from outpatients throughout southern Germany.
Nineteen were from patients suffering from urinary tract
infections, while the origin of the remaining strains was not
specified further. More than one isolate from the same
patient, or isolates from associated patients, were excluded.
L. adecarboxylata ATCC 23375 (isolated from Mangifera indica,
South Africa), LMG 2775 (human eye, USA), LMG 2776
(drinking water, geographical origin not available), LMG 2777
(human knee fluid, geographical origin not available), LMG
2798, LMG 2799 and LMG 2800 (all drinking water, France)
served as reference strains and were purchased from the
Belgian Coordinated Collections of Microorganisms
(BCCM ⁄LMG, Ghent, Belgium). The last two strains and
E. coli ATCC 25922 also served as controls for antibiotic
susceptibility testing. E. coli ATCC 25922 was obtained from
the German Culture Collection of Microorganisms and Cell
Cultures (DSMZ, Braunschweig, Germany).
Identification
Identification was undertaken with two commercial identifi-
cation systems for Enterobacteriaceae and related bacteria,
namely Micronaut-E (Merlin-Diagnostika, Bornheim, Ger-
many) and API 20E (bioMe´rieux, Marcy l’Etoile, France), and
seven conventional tests. The tests were performed twice and
were carried out with either all the strains (Micronaut-E
and conventional tests) or with 25 representative strains (API
20E). Conventional tests comprised six sugar fermentation
tests and production of yellow pigment. Sugar fermentation
tests were performed on bromocresol purple agar (Difco
Laboratories, Detroit, MI, USA) plates, supplemented with
0.5% w ⁄v of either adonitol, D-arabitol, D-cellobiose, dulcitol,
D-lactose or D-melibiose; yellow pigment production was
tested on IsoSensitest agar (Oxoid, Basingstoke, UK). The
commercial tests were performed according to the manufac-
turer’s instructions. For all tests, incubation was at 37C, and
reading was done after 24 h. For conventional tests, reading
was also done after 48 h.
Antibiotics and antibiotic susceptibility testing
Antibiotic susceptibilities were tested with a microdilution
procedure in cation-adjusted Mueller–Hinton broth (CAMHB;
Difco). Twenty representative strains were also tested in
IsoSensitest broth (Oxoid). After inoculation of antibiotic-
containing microtitration plates (Merlin-Diagnostika) with
100 lL of bacterial suspension (3–7 · 105 CFU ⁄mL), and incu-
bation for 22 h at 37C, MIC values were determined with a
photometer for microtitration plates (Multiscan Multisoft;
Labsystems, Helsinki, Finland), and controlled by eye. The
MIC was defined as the lowest concentration that inhibited
visible bacterial growth. All antibiotics were kindly supplied
by the manufacturers to Merlin-Diagnostika, who produced
the antibiotic-containing plates.
Evaluation of natural antibiotic susceptibility
Plotting the MIC of a particular antibiotic for one species
against the number of strains found with the respective MIC
usually results in a bimodal distribution. Generally, one peak
with relatively low MICs represents the natural population,
and one peak with higher MICs represents the strains with
acquired (secondary) resistance. Analysis of the MIC distribu-
tion of all strains of one species for each antibiotic permits
determination of the biological thresholds, which limit the
natural population at high MICs, but not those strains with
secondary resistance. The MIC values of the natural popula-
tion were investigated to assess whether they were above or
below the breakpoints of the standards used to assess clinical
susceptibility. When the natural population was sensitive or
intermediate according to the cited standard, it was described
as naturally sensitive or naturally intermediate, as appropriate.
When the natural population was clinically resistant, it was
described as naturally (intrinsically) resistant. The method has
been described in detail previously [22]. In the present study,
breakpoints according to the German standard (Deutsches
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Institut fu¨r Normung, DIN) were applied [23]. For antibiotics
for which DIN clinical assessment criteria do not exist,
breakpoints were employed according to French [24], Swedish
[25] or USA standards [26]. Breakpoints for ketolides were
those proposed by Stone et al. [27] for ABT-773 and Soussy
et al. [28] for telithromycin. Linezolid breakpoints were those
proposed by the European Committee on Antimicrobial
Susceptibility Testing [29]. Breakpoints for apramycin, ribo-
stamycin and lividomycin A were as published recently [30].
RESULTS
Identification
Of 100 strains from clinical sources in southern
Germany that were labelled originally as
‘L. adecarboxylata’, 94 were clearly attributable to
this species (Table 1). Among the six remaining
strains, there were two strains of Escherichia
vulneris and one strain of an unspecified Shigella
species, as well as three citrate-positive, adonitol-
and arabitol-negative strains that were not clearly
identifiable. Surprisingly, 24 leclerciae produced
acid from sorbitol but not from adonitol, a
phenotypic pattern characteristic of E. coli [21].
In contrast to E. coli, all these isolates were unable
to express lysine decarboxylase, but assimilated
malonate and produced acid from arabitol and
cellobiose. All the strains tested showed the same
results with both the Micronaut-E and the API
20E systems. Using the Micronaut-E system alone,
sorbitol-positive, adonitol-negative strains were
identified as ‘Pantoea agglomerans’, whereas they
were identifed as L. adecarboxylata by API 20E
(data not shown). The identification of the strains
of the Belgian Coordinated Collections of Micro-
organisms was confirmed with Micronaut-E and
API 20E; among these strains, there were no
atypical leclerciae.
Table 1. Biochemical properties of the Leclercia adecarboxylata strains testeda
Positive reactions (%)
L. adecarboxylata E. coli E. coli (inactive)
Biochemical Test Method This study Tamura et al. [4] Farmer [21] Farmer [21] Farmer [21]
Amino-acid deaminase MCN-E, API20E 0 0 0 0 0
Arginine dihydrolase MCN-E, API20E 0 0 0 17 3
b-Galactosidase (ONPG)b MCN-E, API20E 99 100 100 95 45
Gelatinase API20E 12 0 0 0 0
b-Glucosidase (aesculin hydrol.) MCN-E, API20E 100 100 100 35 5
b-Glucuronidase (PGUR)c MCN-E 0 0 NT NT NT
H2S-production MCN-E, API20E 0 0 0 1 1
Lysine decarboxylase MCN-E, API20E 0 0 0 90 40
Ornithine decarboxylase MCN-E, API20E 0 0 0 65 20
Tryptophanase (indole production) MCN-E, API20E 100 100 100 98 80
Urease MCN-E, API20E 12 10 48 1 1
Voges-Proskauer Test MCN-E, API20E 0 0 0 0 0
b-Xylosidase (ONPX)d MCN-E 94 100 NT NT NT
Yellow pigment Plate test (48h) 19 14 37 0 0
Assimilation of
Citrate MCN-E, API20E 0 0 0 1 1
Malonate MCN-E 100 100 93 0 0
Fermentation of
Adonitol MCN-E Plate test 73 98 93 5 3
Amygdalin API20E 100 NT (99e) NT (99e) NT(20e) NT(12e)
L-Arabinose API20E 100 100 100 99 85
D-Arabitol Plate test (48h) 91 96 96 5 5
D-Cellobiose Plate test (48h) 100 100 100 2 2
Dulcitol Plate test (48h) 90 87 86 60 40
Glucose MCN-E 100 100 100 100 100
myo-Inositol MCN-E 3 0 0 1 1
D-Lactose Plate test (48h) 90 100 93 95 20
D-Mannitol API20E 100 100 100 98 93
D-Melibiose API20E Plate test (48h) 100 100 100 75 40
Raffinose API20E 68 59 66 50 15
L-Rhamnose MCN-E, API20E 99 100 100 80 65
D-Sorbitol MCN-E, API20E 25 9 0 94 75
Sucrose MCN-E, API20E 42 52 66 50 15
D-Xylose MCN-E 100 100 100 95 70
aThe results are contrasted with the data of Tamura et al. [4] and Farmer [21]. Discriminating features are shown in the shaded areas. It should be noted that the results of
Farmer were obtained after a 48-h-incubation.
bCleavage of o-nitrophenyl-b-galactopyranoside, cp-nitrophenyl-b-glucuronide, do-nitrophenyl-b-xyloside, eaccording to the API20E database. NT, not tested or no information
available.
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Table 2. Antibiotic susceptibility of Leclercia adecarboxylataa
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Antibiotic susceptibility patterns and natural
susceptibility
The antimicrobial susceptibilities of L. adecarb-
oxylata are shown in Table 2. Evaluation of these
data revealed that strains of Leclercia were
naturally sensitive to all tested aminoglycosides
and tetracyclines, all but two b-lactam
antibiotics, quinolones, folate pathway inhibi-
tors, azithromycin, chloramphenicol and nitro-
furantoin. Natural resistance was found with
oxacillin, benzylpenicillin, erythromycin, roxith-
romycin and clarithromycin, ketolides, lincosa-
mides, dalfopristin–quinupristin, fusidic acid,
glycopeptides, linezolid, rifampicin and fosfo-
mycin.
Medium dependency in susceptibility testing
For most of the tested antibiotics, there were only
minor medium-dependent differences in suscep-
tibility. The greatest differences were found with
macrolides, ketolides, tetracyclines and fosfomy-
cin. The MICs of these antibiotics in IsoSensitest
broth were two (azithromycin and fosfomycin),
one to two (clarithromycin, doxycycline and
minocycline) or one (roxithromycin, tetracycline,
telithromycin and ABT-773) doubling dilution
step(s) higher than in CAMHB (data not shown).
Medium dependencies did not affect clinical
assessment criteria.
Quality assurance
Within the permissible margin of error, the MICs
of all antibiotics in both media were reproducible
for L. adecarboxylata strains LMG 2799, LMG 2800
and E. coli ATCC 25922. With few exceptions, the
MICs for E. coli ATCC 25922 in CAMHB and
IsoSensitest broth were within the control limits
for susceptibility testing according to DIN and
National Committee for Clinical Laboratory
Standards criteria (data not shown).
DISCUSSION
Several studies have been published which indi-
cate the role of L. adecarboxylata as an opportun-
istic pathogen, but the total number of published
cases of infections associated with this organism
is currently too small to allow a proper estimation
of its actual clinical significance. In some cases,
L. adecarboxylata has been isolated from patients
with mixed microbial infection, which raises
questions concerning the organism’s role in some
of these infections [16,19,20]. L. adecarboxylata has
Table 2. Continued
aThe number of strains for the corresponding MIC value is cited. A number in the lowest concentration of the antibiotic represents the maximal MIC value at this concentration
(MIC = cmin ﬁ MIC £ cmin). An MIC value higher than the highest concentration tested is cited in the subsequent higher concentration step. MIC values in shaded areas
indicate the clinically intermediate area according to the standard applied. A thick black line indicates the breakpoint between the clinically sensitive and clinically resistant
strains, if the interpretation ‘intermediate’ does not exist.
DIN, Deutsches Institut fu¨r Normung e.V.; EUCAST, European Committee on Antimicrobial Susceptibility Testing; NCCLS, National Committee for Clinical Laboratory
Standards; SFM, Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise de Microbiologie Communique´.
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been found to cause infections mainly in immu-
nocompromised patients or patients with under-
lying medical conditions. The variety of diseases
caused by this organism, e.g., sepsis and septic
arthritis [18,20], diarrhoea [9], peritonitis [14,19]
and gall bladder infections [13], is a typical feature
of numerous Enterobacteriaceae species acting as
opportunistic pathogens. The present study inves-
tigated 101 leclerciae isolated predominantly from
clinical specimens in southern Germany. Interest-
ingly, all German leclerciae were isolated from
outpatients, and at least 19 of them were from
patients suffering from urinary tract infection.
Although there is no information on the clinical
significance of these strains, the frequent isolation
from urine samples indicates an association with
urinary tract infection for at least some strains,
although the urinary tract is not cited in the
literature as a site of Leclercia infection. In 1989,
Richard [6] reviewed the origin of Leclercia and
described urine isolates of this species, but with-
out any annotations concerning their clinical
importance. Because of the findings of the present
study, it may be justified to challenge the actual
frequency of Leclercia infections, particularly if the
high degree of phenotypic similarity between
Leclercia and E. coli, one of the most important
human pathogens, is also considered.
The present study found that 24% of all
Leclercia strains produced acid from sorbitol but
not from adonitol, a phenotypic pattern charac-
teristic of E. coli (Table 1) [21]. Fermentation of
sorbitol and failure to produce acid from adonitol
has been reported for some leclerciae [4,21], but
the frequency of these features has been consid-
ered to be rare and there is no information about a
concomitant appearance of these properties. In
spite of these unusual features, all Leclercia strains
in the present study were identified unambigu-
ously as L. adecarboxylata by the API 20E system.
Using the Micronaut-E system, sorbitol-positive
and adonitol-negative leclerciae were erroneously
assigned to P. agglomerans1 . This kind of misiden-
tification was not surprising, and must be attrib-
uted to the Micronaut-E database, which
combines several species of the Erwinia herbicola–
Enterobacter agglomerans complex into the mono-
phyletic species P. agglomerans (data not shown).
According to our data and those of the literature,
L. adecarboxylata and P. agglomerans can be differ-
entiated unambiguously from each other by
testing the indole reaction, acid production from
melibiose and dulcitol (negative for P. agglomer-
ans, positive for Leclercia), and the Voges–Proska-
uer reaction (positive for P. agglomerans, negative
for Leclercia) (Table 1) [4,21,31]. A phenotypic
Table 3. Antibiotic susceptibility patterns of Leclercia adecarboxylata strains published in the literature6
Study
Method
(standard)
Number
of strains Strain AP AP + I BP OP Ce Ca Az AG FPI Q Ch Co Fo T
Pe´rez-Moreno et al. [18] Not stated
(not stated)
1 Sb Sf NT NT Sm NT NT Sw,x,y Sbb Sdd NT NT R NT
Longhurst and West [16] Not stated
(probably NCCLS)
1 Sc NT NT Sf Sm NT NT Sx Sbb Sdd NT NT NT NT
Rodrı´guez et al. [19] Not stated
(not stated)
1 S?d S?d NT S?d S?d S?d S?d S?d S?d S?d S?d NT R S?d
De Baere7 et al. [13] Agar diffusion 2 1 Sc NT NT Sh,I So Su S Sw,x Sbb See NT NT NT NT
(NCCLS) 2a Rc NT NT Sh Sp Su S Sw,x Sbb Sdd NT NT NT NT
Fattal and Deville [14] Not stated
(probably NCCLS)
1 Sc Sg NT Sh,j Sq Su,v NT Sx,y Sbb S dd,ff NT NT NT NT
Martinez et al. [17] Not stated
(not stated)
1 Sc Sf NT NT Sm Su NT Sw,x Sbb Sdd NT NT NT NT
Temesgen et al. [20] Agar dilution 3 1 Sc NT NT NT Sr Su NT Sw,x Sbb Sdd NT NT NT NT
(NCCLS) 2 Sc NT NT Sk Sr Su S Sw,x Sbb Sdd S NT NT NT
3 Sc NT NT Sk Sr Su S Sw,x Sbb Sdd S NT NT NT
Daza et al. [10] Not stated
(not stated)
1 S?e S?e S?e S?e S?e S?e S?e S? e S?e S?e S?e S?e S?e S?e
Otani8 and Bruckner [12] Microdilution 1 Sc NT NT Sh,k Ss NT NT Sw,x,y Sbb NT NT NT NT NT
(NCCLS)
Tamura et al. [4] Agar diffusion 86 Sc NT R Sl St NT NT Sx,z (S)cc Sgg (S) S NT (S)
(not stated) (S)aa
aSusceptibility pattern probably belongs to Escherichia hermannii; bamoxycillin; campicillin; dsensitive to all antibiotics acting against Gram-negative bacteria (no further
specification), except for fosfomycin; esensitive to all tested antibiotics (no further specification); famoxycillin + clavulanic acid; gampicillin + sulbactam; hpiperacillin;
itemocillin; jtazobactam; kmezlocillin; lcarbenicillin; mcefazolin, cefotaxime and cefuroxime; ncefazolin, cefepime, cefotaxime, ceftazidime, ceftizoxime and cephalothin;
cefuroxime, ceftazidime and ceftriaxone; pcefuroxime and ceftriaxone; qcefazolin, ceftazidime and ceftizoxime; rcefazolin, cefoperazone and ceftazidime; tcephaloridine;
uimipenem; vmeropenem; wamikacin; xgentamicin; ytobramycin; zkanamycin; aastreptomycin; bbco-trimoxazole; ccsulphadiazine; ddciprofloxacin; eefluoroquinolones (no
further specification); ffofloxacin; ggnalidixic acid.
S, sensitive; R, resistant; (S), most strains were sensitive; NT, not tested; AP, aminopenicillins; I, inhibitors; BP, benzylpenicillin; OP, other penicillins (penicillins + inhibitors);
Ce, cephalosporins; Ca, carbapenems; Az, aztreonam; AG, aminoglycosides; FPI, folate pathway inhibitors; Q, quinolones; Ch, chloramphenicol; Co, colistin; Fo, fosfomycin; T,
tetracycline.
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separation of L. adecarboxylata from E. coli should,
however, include assimilation of malonate and
fermentation of arabitol and cellobiose (positive
for Leclercia, negative for E. coli), as well as
expression of lysine decarboxylase (negative for
Leclercia, usually positive for E. coli) (Table 1)
[4,21]. Interpretation of test results for acid pro-
duction from adonitol and sorbitol should be
undertaken with care.
There are few published studies in the litera-
ture dealing with antimicrobial susceptibility
patterns of L. adecarboxylata (Table 3). In all cases,
only a small number of antibiotics (up to a
maximum of 13) and—apart from one study
[4]—only single [12,16–19] or two or three strains
[13,20] have been investigated. Data on the nat-
ural antimicrobial susceptibilities of L. adecarboxy-
lata are not available. In the largest published
study on Leclercia, Tamura et al. [4] exam-
ined—together with genetic and biochemical data
useful for the species description of L. adecarboxy-
lata—the susceptibility of 86 leclerciae to 12
antimicrobial agents (Table 3). Most strains exam-
ined were sensitive to all tested antimicrobial
agents, apart from benzylpenicillin. Considering
this and other published data, there is evidence
that L. adecarboxylata is naturally sensitive to
numerous antimicrobial agents.
In the present study, it was shown that strains of
L. adecarboxylata were naturally sensitive to tetra-
cyclines, aminoglycosides, all but two b-lactams,
quinolones, folate pathway inhibitors, chloram-
phenicol, nitrofurantoin and azithromycin, but
were naturally resistant to penicillin G, oxacillin,
erythromycin, roxithromycin, clarithromycin,
ketolides, lincosamides, streptogramins, linezolid,
glycopeptides, rifampicin, fusidic acid and—inter-
estingly—fosfomycin. Resistance of L. adecarboxy-
lata to the latter agent has also been mentioned in
the case reports published most recently by Rod-
rı´guez et al. [19] and Pe´rez-Moreno et al. [18]
(Table 3). Natural fosfomycin resistance may be
of clinical interest for the following reasons. In
several countries, fosfomycin is used as an import-
ant therapeutic agent against osteomyelitis and
uncomplicated urinary tract infections, where
species of Enterobacteriaceae (and probably also
L. adecarboxylata) are involved. In addition, the
natural fosfomycin resistance of L. adecarboxylata
may represent an additional parameter for its
reliable phenotypic separation from E. coli: the
latter species is naturally sensitive to fosfomycin
(MICs for 90% of strains in the natural population
were 0.5–2 mg ⁄L) [32], and the degree of acquired
fosfomycin resistance in E. coli is generally low
(0–1.5% in Europe) [33].
The genotype of natural resistance to fosfomy-
cin in L. adecarboxylata is completely unknown
and might be attributed to one of a range of
different mechanisms. From the fosfomycin MICs
in the present study, it is obvious that there is no
naturally occurring high-level resistance in this
species. Therefore, it can be assumed that reduced
permeability of the cell envelope to this agent,
rather than a specific fosfomycin:glutathione-
S-transferase, might be associated with the phe-
notype observed. Alternatively, a transferase with
low affinity for fosfomycin, or low-level enzyme
expression, could be responsible [34].
Apart from fosfomycin, the natural resistances
found in the present study were not unexpected,
since these patterns represent a typical feature of
most Enterobacteriaceae; they are likely to be
caused predominantly by drug exclusion by the
cell envelope [35]. For example, it must be
assumed that vancomycin and rifampicin cannot
pass through the Leclercia outer-membrane (OM)
because of their large molecular sizes; both agents
exceed the maximum size for entry into the cell
through the OmpF porins of E. coli [36]. Other
antibiotics, such as some macrolides, lincosa-
mides, fusidic acid and streptogramins, probably
do not pass through the OM because of their
hydrophobic moieties: In general, the OM consti-
tutes an efficient barrier against these lipophilic
agents [35]. It should be mentioned that the
observed resistance of L. adecarboxylata to all
macrolides, except azithromycin, is also a com-
mon antimicrobial phenotype found in numerous
Enterobacteriaceae. The dicationic azalide azith-
romycin diffuses better than most other macro-
lides through the unspecific and hydrophilic OM
porin channels and, in addition, interacts with the
acidic lipopolysaccharide and penetrates the OM
by virtue of this interaction [37,38].
In conclusion, the present study provides a
database of the natural susceptibility of
L. adecarboxylata to a wide range of antimicrobial
agents, as well as some information about its
biochemical features. These data can be applied to
the validation of forthcoming antibiotic suscepti-
bility tests of this microorganism and may con-
tribute to its reliable identification. Apart from
fosfomycin, natural antimicrobial susceptibility
Stock et al. Susceptibility and identification of L. adecarboxylata 731
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 724–733
patterns did not indicate therapeutic difficulties
for treatment of Leclercia infections. Special atten-
tion should be paid to aberrant leclerciae that
resemble E. coli in numerous biochemical proper-
ties. Fosfomycin susceptibility might be a helpful
parameter allowing differentiation of L. adecarb-
oxylata and E. coli.
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